Trial Profile
A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-beta-1a 30 mcg IM Weekly in Subjects with Relapsing-Remitting Multiple Sclerosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2018
Price :
$35
*
At a glance
- Drugs Ceralifimod (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors Merck KGaA
- 27 Dec 2014 Status changed from recruiting to discontinued, according to European Clinical Trials Database (EudraCT2013-002351-15) record.
- 27 Dec 2014 Status changed from recruiting to discontinued, according to European Clinical Trials Database (EudraCT2013-002351-15) record.
- 07 Apr 2014 New trial record